UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022
UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive ovarian cancer, expected to initiate in Q2 2022
Interim data from UPGRADE dose escalation umbrella trial of UpRi in combination with platinum planned for 2H 2022
Phase 1 dose escalation studies for two first-in-class candidates, XMT-1660, a Dolasynthen B7-H4 targeted ADC and XMT-2056, an Immunosynthen STING-agonist ADC targeting HER2, both expected to initiate in mid-2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided its strategic priorities and anticipated milestones for 2022. Anna Protopapas, President and CEO of Mersana Therapeutics, Inc. will provide a business update at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.
https://finance.yahoo.com/news/mersana-therapeutics-announces-2022-strategic-130000188.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.